See more : Hangzhou Flariant Co., Ltd. (605566.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Allogene Therapeutics, Inc. (ALLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allogene Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SK Growth Opportunities Corporation (SKGRU) Income Statement Analysis – Financial Results
- Shanghai Guao Electronic Technology Co., Ltd. (300551.SZ) Income Statement Analysis – Financial Results
- China Isotope & Radiation Corporation (1763.HK) Income Statement Analysis – Financial Results
- MAV Beauty Brands Inc. (MAVBF) Income Statement Analysis – Financial Results
- Inventure Growth & Securities Limited (INVENTURE.NS) Income Statement Analysis – Financial Results
Allogene Therapeutics, Inc. (ALLO)
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 95.00K | 243.00K | 38.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.91M | 16.73M | 13.07M | 11.54M | 5.03M | 1.50M | 0.00 |
| Gross Profit | -242.82M | -16.49M | 25.42M | -11.54M | -5.03M | -1.50M | 0.00 |
| Gross Profit Ratio | -255,598.95% | -6,783.95% | 66.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 242.91M | 256.39M | 220.18M | 192.99M | 144.54M | 151.86M | 0.00 |
| General & Administrative | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 24.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -22.00K |
| SG&A | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 2.00K |
| Other Expenses | 13.25M | -1.75M | -2.93M | -1.14M | -268.00K | -21.21M | 0.00 |
| Operating Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Cost & Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Interest Income | 18.31M | 4.57M | 1.71M | 9.16M | 17.35M | 5.79M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.36M | 0.00 |
| Depreciation & Amortization | 14.20M | 14.30M | 10.45M | 11.54M | 5.03M | 1.50M | 24.00K |
| EBITDA | -300.29M | -321.24M | -169.74M | -250.81M | -179.90M | -206.76M | 22.00K |
| EBITDA Ratio | -316,097.89% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -327.74M | -335.45M | -255.79M | -258.24M | -202.01M | -192.84M | -2.00K |
| Operating Income Ratio | -344,986.32% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 472.00K | -4.88M | -1.86M | 8.02M | 17.08M | -18.78M | -22.00K |
| Income Before Tax | -327.27M | -332.63M | -257.01M | -250.22M | -184.93M | -211.62M | -2.00K |
| Income Before Tax Ratio | -344,489.47% | -136,885.60% | -667.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.82M | -12.17M | -16.75M | -331.00K | -117.00K | -24.00K |
| Net Income | -327.27M | -329.82M | -244.84M | -233.47M | -184.59M | -211.51M | -2.00K |
| Net Income Ratio | -344,489.47% | -135,726.34% | -636.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| EPS Diluted | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| Weighted Avg Shares Out | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
| Weighted Avg Shares Out (Dil) | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation - Allogene Therapeutics (NASDAQ:ALLO), ARK Innovation ETF (ARCA:ARKK)
Source: https://incomestatements.info
Category: Stock Reports